Cargando…

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

Intra-tumor heterogeneity represents a major barrier to anti-cancer therapies. One strategy to minimize this limitation relies on bystander effects via diffusion of cytotoxins from targeted cells. Hypoxia-activated prodrugs (HAPs) have the potential to exploit hypoxia in this way, but robust methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Cho R., Bogle, Gib, Wang, Jingli, Patel, Kashyap, Pruijn, Frederik B., Wilson, William R., Hicks, Kevin O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153434/ https://www.ncbi.nlm.nih.gov/pubmed/30279659 http://dx.doi.org/10.3389/fphar.2018.01013

Ejemplares similares

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022)

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
por: Mao, Xinjian, et al.
Publicado: (2018)

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
por: Gu, Yongchuan, et al.
Publicado: (2017)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
por: Dachs, Gabi U., et al.
Publicado: (2009)

Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System
por: Sharrock, Abigail V., et al.
Publicado: (2021)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

On-Lattice Simulation of T Cell Motility, Chemotaxis, and Trafficking in the Lymph Node Paracortex
por: Bogle, Gib, et al.
Publicado: (2012)

A virtual lymph node model to dissect the requirements for T-cell activation by synapses and kinapses
por: Moreau, Hélène D, et al.
Publicado: (2016)

Editorial: Prodrug design and therapeutic applications
por: Xiao, Qicai, et al.
Publicado: (2023)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

Chinese medicinal herbs as potential prodrugs for obesity
por: Law, Siu Kan, et al.
Publicado: (2022)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
por: Cheng, T L, et al.
Publicado: (1999)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

Expanding the toolbox of metabolically stable lipid prodrug strategies
por: Toti, Kiran S., et al.
Publicado: (2023)

Enamine N-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents
por: Kang, Dahye, et al.
Publicado: (2021)

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors
por: Hay, Michael P., et al.
Publicado: (2019)

Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning
por: Langhans, Sigrid A.
Publicado: (2018)

Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug
por: DONG, Xinrui, et al.
Publicado: (2017)

Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs
por: Deng, Chaoyi, et al.
Publicado: (2022)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Esters of valerenic acid as potential prodrugs
por: Hintersteiner, Juliane, et al.
Publicado: (2014)

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs
por: Liang, Dinghua, et al.
Publicado: (2018)

Rutin bioconjugates as potential nutraceutical prodrugs: An in vitro and in ovo toxicological screening
por: Dehelean, Cristina Adriana, et al.
Publicado: (2022)

Amplifying the efficacy of ALA-based prodrugs for photodynamic therapy using nanotechnology
por: Lou, Liang, et al.
Publicado: (2023)

Hypoxia and Hypoxia-Inducible Factors in Lymphedema
por: Jiang, Xinguo, et al.
Publicado: (2022)

Resveratrol activates CD8(+) T cells through IL-18 bystander activation in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2022)

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
por: Aapro, Matti, et al.
Publicado: (2019)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
por: Omran, Ziad, et al.
Publicado: (2021)

A Nanomicellar Prodrug Carrier Based on Ibuprofen-Conjugated Polymer for Co-delivery of Doxorubicin
por: Li, Zuojun, et al.
Publicado: (2018)

Synergistic Effect of Retinoic Acid Polymeric Micelles and Prodrug for the Pharmacodynamic Evaluation of Tumor Suppression
por: Zhu, Yan-Hua, et al.
Publicado: (2019)

Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport
por: Quach, Tim, et al.
Publicado: (2022)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

Three-Dimensional Culture of Ameloblast-Originated HAT-7 Cells for Functional Modeling of Defective Tooth Enamel Formation
por: Földes, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b50nargc8uo19hig491uu90487